Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer A Cohort Study

被引:8
|
作者
Kolomeyevskaya, Nonna V. [1 ]
Szender, J. Brian [1 ]
Zirpoli, Gary [2 ]
Minlikeeva, Albina [2 ]
Friel, Grace [2 ]
Cannioto, Rikki A. [2 ]
Brightwell, Rachel M. [1 ]
Grzankowski, Kassondra S. [1 ]
Moysich, Kirsten B. [2 ]
机构
[1] Roswell Pk Canc Inst, Dept Gynecol Oncol, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Canc Prevent & Control, Buffalo, NY 14263 USA
关键词
Reproductive characteristics; Oral contraceptives; Parity; Ovarian cancer survival; RISK-FACTORS;
D O I
10.1097/IGC.0000000000000540
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives Prognostic risk factors influencing survival in patients with epithelial ovarian cancer (EOC) include tumor stage, grade, histologic subtype, debulking, and platinum status. Little is known about the impact of hormonal milieu and reproductive factors before cancer diagnosis on clinical outcome. We sought to evaluate whether oral contraceptive (OC) use carries any prognostic significance on overall survival (OS) in patients with EOC. Methods Newly diagnosed patients with EOC, fallopian tube, and primary peritoneal cancers between 1982 and 1998 were prospectively evaluated with a comprehensive epidemiologic questionnaire. A retrospective chart review was performed to abstract clinicopathologic data, including OS. A Kaplan-Meier analysis was performed to compare survival across various exposures. A Cox regression model was used to compute adjusted hazards ratios (aHRs) and 95% confidence intervals (CIs). Results We identified 387 newly diagnosed cancers with evaluable information in this cohort. Decreased risk of death was observed in women who reported prior use of OC (aHR, 0.79; 95% CI, 0.58-1.09), previous pregnancy (aHR, 0.77; 95% CI, 0.57-1.04), or a live birth (aHR, 0.81; 95% CI, 0.60-1.08) after adjusting for age at diagnosis, stage, and histologic subtype. Oral contraceptive use was associated with a crude reduced risk of death (HR, 0.55; 95% CI, 0.42-0.72), with reported median OS of 81 months in OC users versus 46 months in nonusers. Patients who reported a single live birth experienced the largest potential survival advantage (aHR, 0.61; 95% CI, 0.39-0.94). Oral contraceptive use and prior pregnancy were associated with improved survival across all strata. Conclusions Oral contraceptive use may have lasting effects on epithelial ovarian tumor characteristics conferring favorable prognosis. Putative mechanisms that affect tumor biology include complex interactions between ovarian cells, host immune cells, and hormonal microenvironment during carcinogenesis. Future efforts should be directed to determine the role of reproductive factors in antitumor immunity.
引用
收藏
页码:1587 / 1592
页数:6
相关论文
共 50 条
  • [1] Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study
    Jelena Bešević
    Marc J Gunter
    Renée T Fortner
    Konstantinos K Tsilidis
    Elisabete Weiderpass
    N Charlotte Onland-Moret
    Laure Dossus
    Anne Tjønneland
    Louise Hansen
    Kim Overvad
    Sylvie Mesrine
    Laura Baglietto
    Françoise Clavel-Chapelon
    Rudolf Kaaks
    Krasimira Aleksandrova
    Heiner Boeing
    Antonia Trichopoulou
    Pagona Lagiou
    Christina Bamia
    Giovanna Masala
    Claudia Agnoli
    Rosario Tumino
    Fulvio Ricceri
    Salvatore Panico
    HB(as) Bueno-de-Mesquita
    Petra H Peeters
    Mie Jareid
    J Ramón Quirós
    Eric J Duell
    María-José Sánchez
    Nerea Larrañaga
    María-Dolores Chirlaque
    Aurelio Barricarte
    Joana A Dias
    Emily Sonestedt
    Annika Idahl
    Eva Lundin
    Nicholas J Wareham
    Kay-Tee Khaw
    Ruth C Travis
    Sabina Rinaldi
    Isabelle Romieu
    Elio Riboli
    Melissa A Merritt
    British Journal of Cancer, 2015, 113 : 1622 - 1631
  • [2] Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study
    Besevic, Jelena
    Gunter, Marc J.
    Fortner, Renee T.
    Tsilidis, Konstantinos K.
    Weiderpass, Elisabete
    Onland-Moret, N. Charlotte
    Dossus, Laure
    Tjonneland, Anne
    Hansen, Louise
    Overvad, Kim
    Mesrine, Sylvie
    Baglietto, Laura
    Clavel-Chapelon, Francoise
    Kaaks, Rudolf
    Aleksandrova, Krasimira
    Boeing, Heiner
    Trichopoulou, Antonia
    Lagiou, Pagona
    Bamia, Christina
    Masala, Giovanna
    Agnoli, Claudia
    Tumino, Rosario
    Ricceri, Fulvio
    Panico, Salvatore
    Bueno-de-Mesquita, H. B.
    Peeters, Petra H.
    Jareid, Mie
    Ramon Quiros, J.
    Duell, Eric J.
    Sanchez, Maria-Jose
    Larranaga, Nerea
    Chirlaque, Maria-Dolores
    Barricarte, Aurelio
    Dias, Joana A.
    Sonestedt, Emily
    Idahl, Annika
    Lundin, Eva
    Wareham, Nicholas J.
    Khaw, Kay-Tee
    Travis, Ruth C.
    Rinaldi, Sabina
    Romieu, Isabelle
    Riboli, Elio
    Merritt, Melissa A.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1622 - 1631
  • [3] Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk
    Cook, Linda S.
    Pestak, Claire R.
    Leung, Andy C. Y.
    Steed, Helen
    Nation, Jill
    Swenerton, Kenneth
    Gallagher, Richard
    Magliocco, Anthony
    Kobel, Martin
    Brooks-Wilson, Angela
    Le, Nhu
    BRITISH JOURNAL OF CANCER, 2017, 116 (02) : 265 - 269
  • [4] Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk
    Linda S Cook
    Claire R Pestak
    Andy CY Leung
    Helen Steed
    Jill Nation
    Kenneth Swenerton
    Richard Gallagher
    Anthony Magliocco
    Martin Köbel
    Angela Brooks-Wilson
    Nhu Le
    British Journal of Cancer, 2017, 116 : 265 - 269
  • [5] Short-term oral contraceptive use and the risk of epithelial ovarian cancer
    Greer, JB
    Modugno, F
    Allen, GO
    Ness, RB
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 162 (01) : 66 - 72
  • [6] Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
    Tsilidis, K. K.
    Allen, N. E.
    Key, T. J.
    Dossus, L.
    Lukanova, A.
    Bakken, K.
    Lund, E.
    Fournier, A.
    Overvad, K.
    Hansen, L.
    Tjonneland, A.
    Fedirko, V.
    Rinaldi, S.
    Romieu, I.
    Clavel-Chapelon, F.
    Engel, P.
    Kaaks, R.
    Schuetze, M.
    Steffen, A.
    Bamia, C.
    Trichopoulou, A.
    Zylis, D.
    Masala, G.
    Pala, V.
    Galasso, R.
    Tumino, R.
    Sacerdote, C.
    Bueno-de-Mesquita, H. B.
    van Duijnhoven, F. J. B.
    Braem, M. G. M.
    Onland-Moret, N. C.
    Gram, I. T.
    Rodriguez, L.
    Travier, N.
    Sanchez, M-J
    Huerta, J. M.
    Ardanaz, E.
    Larranaga, N.
    Jirstrom, K.
    Manjer, J.
    Idahl, A.
    Ohlson, N.
    Khaw, K-T
    Wareham, N.
    Mouw, T.
    Norat, T.
    Riboli, E.
    BRITISH JOURNAL OF CANCER, 2011, 105 (09) : 1436 - 1442
  • [7] Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
    Jatoi, Aminah
    Foster, Nathan R.
    Kalli, Kimberly R.
    Vierkant, Robert A.
    Zhang, Zhiying
    Larson, Melissa C.
    Fridley, Brooke
    Goode, Ellen L.
    BMC CANCER, 2015, 15
  • [8] Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
    Aminah Jatoi
    Nathan R. Foster
    Kimberly R. Kalli
    Robert A. Vierkant
    Zhiying Zhang
    Melissa C. Larson
    Brooke Fridley
    Ellen L. Goode
    BMC Cancer, 15
  • [9] Timing of births and oral contraceptive use influences ovarian cancer risk
    Wu, Anna H.
    Pearce, Celeste Leigh
    Lee, Alice W.
    Tseng, Chiuchen
    Jotwani, Anjali
    Patel, Prusha
    Pike, Malcolm C.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (12) : 2392 - 2399
  • [10] Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity
    K J Wernli
    P A Newcomb
    J M Hampton
    A Trentham-Dietz
    K M Egan
    British Journal of Cancer, 2008, 98 : 1781 - 1783